Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
暂无分享,去创建一个
B. Ebert | A. Ganser | T. Haferlach | A. Órfão | P. Greenberg | W. Hofmann | M. Béné | J. Bennett | M. Lübbert | D. Steensma | K. Sotlar | M. Loken | P. Valent | M. Pfeilstöcker | W. Sperr | U. Germing | L. Malcovati | A. Giagounidis | A. A. van de Loosdrecht | R. Stauder | H. Horny | G. Hoermann | K. Ogata | D. Wells | D. Haase | J. Schanz | A. Orazi | T. Westers | P. Bettelheim
[1] D. Girelli,et al. Anemia in the Elderly , 2018, HemaSphere.
[2] J. Bennett,et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. , 2017, Leukemia research.
[3] P. D. Dal Cin,et al. Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome , 2017, Leukemia & lymphoma.
[4] A. Órfão,et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group , 2017, Haematologica.
[5] V. V. D. van der Velden,et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes , 2017, Haematologica.
[6] A. LaCasce,et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. McLeod,et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. , 2017, The Lancet. Oncology.
[8] M. Cazzola,et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. , 2016, Blood.
[9] R. Bejar,et al. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study , 2016, BMC Cancer.
[10] J. Bennett,et al. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?). , 2016, Leukemia research.
[11] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[12] G. Ossenkoppele,et al. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system , 2016, Leukemia.
[13] G. Ossenkoppele,et al. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. , 2016, European journal of cancer.
[14] Wanlong Ma,et al. Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome. , 2016, Genetic testing and molecular biomarkers.
[15] D. Arber,et al. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. , 2015, Hematology. American Society of Hematology. Education Program.
[16] M. Cazzola,et al. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). , 2015, Hematology. American Society of Hematology. Education Program.
[17] U. Germing,et al. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes , 2015, European journal of haematology.
[18] B. Ebert,et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.
[19] P. M. van de Ven,et al. Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes , 2015, Haematologica.
[20] E. Duncavage,et al. The utility of next‐generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes , 2015, International journal of laboratory hematology.
[21] T. Haferlach,et al. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients , 2015, Cytometry. Part B, Clinical cytometry.
[22] A. Kohlmann,et al. Mutational profiling in patients with MDS: ready for every-day use in the clinic? , 2015, Best practice & research. Clinical haematology.
[23] S. Gore,et al. Current state of prognostication and risk stratification in myelodysplastic syndromes , 2015, Current opinion in hematology.
[24] G. Ehninger,et al. Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring , 2015, Haematologica.
[25] F. Solé,et al. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group , 2015, Haematologica.
[26] M. Loken,et al. Assessment of erythroid dysplasia by “Difference from normal” in routine clinical flow cytometry workup , 2014, Cytometry. Part B, Clinical cytometry.
[27] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[28] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[29] G. Ossenkoppele,et al. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes , 2014, British journal of haematology.
[30] P. Campbell,et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes , 2014, Leukemia.
[31] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[32] G. Ossenkoppele,et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. , 2014, Cytometry. Part B, Clinical cytometry.
[33] A Orfao,et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS , 2014, Leukemia.
[34] A. Giagounidis,et al. Morphology, cytogenetics and classification of MDS. , 2013, Best practice & research. Clinical haematology.
[35] P. Fenaux,et al. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. , 2013, Best practice & research. Clinical haematology.
[36] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[37] R. Chen,et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia , 2013, American journal of hematology.
[38] R. Schlenk,et al. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. , 2013, Leukemia research.
[39] P. Valent. Low blood counts: immune mediated, idiopathic, or myelodysplasia. , 2012, Hematology. American Society of Hematology. Education Program.
[40] H. Johnsen,et al. Cancer stem cell definitions and terminology: the devil is in the details , 2012, Nature Reviews Cancer.
[41] Peter J. Campbell,et al. Evolution of the cancer genome , 2012, Nature Reviews Genetics.
[42] D. Steensma. Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors , 2012, Current Hematologic Malignancy Reports.
[43] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[44] Mithat Gonen,et al. Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.
[45] F. Solé,et al. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? , 2012, Leukemia research.
[46] U. Germing,et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. , 2012, Leukemia research.
[47] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] A. Órfão,et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.
[49] B. Bain,et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. , 2011, Leukemia research.
[50] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[51] E. Estey,et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Benjamin L Ebert,et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] P. Valent,et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. , 2011, American journal of cancer research.
[54] U. Germing,et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] W. Kern,et al. Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS) , 2010, Oncotarget.
[56] K. Sotlar,et al. Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review , 2010, Pathobiology.
[57] G. Ossenkoppele,et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. , 2010, Blood.
[58] J. Salk. Clonal evolution in cancer , 2010 .
[59] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[60] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[61] P. Valent,et al. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions , 2009, European journal of clinical investigation.
[62] K. Mitani. [Myelodysplastic syndrome]. , 2020, Nihon rinsho. Japanese journal of clinical medicine.
[63] B. Bain,et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts , 2008, Haematologica.
[64] P. Valent,et al. Impact of age and comorbidity in myelodysplastic syndromes. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[65] D. Haase. Cytogenetic features in myelodysplastic syndromes , 2008, Annals of Hematology.
[66] K. Sotlar,et al. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. , 2007, Leukemia research.
[67] J. Bennett,et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. , 2007, Leukemia research.
[68] T. Haferlach,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.
[69] Z. Zemanová,et al. Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. , 2007, Leukemia research.
[70] H. Tamura,et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. , 2006, Blood.
[71] G. Mufti,et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow , 2006, Leukemia.
[72] A. Gotoh,et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients , 2005, Leukemia.
[73] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] C. Steidl,et al. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. , 2005, Leukemia research.
[75] J. Bennett,et al. The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment , 2005, Hematology.
[76] M. Cazzola,et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome , 2005, Leukemia.
[77] S. Kajigaya,et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. , 2004, Blood.
[78] H. Deeg,et al. Flow Cytometry for Diagnosis and Assessment of Prognosis in Patients with Myelodysplastic Syndromes , 2004, Hematology.
[79] C. Langford,et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology , 2004, British journal of haematology.
[80] A. Órfão,et al. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. , 2004, The hematology journal : the official journal of the European Haematology Association.
[81] Y. Yamashita,et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome , 2003, British journal of haematology.
[82] H. Deeg,et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.
[83] M. Mori,et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. , 2002, Blood.
[84] H Phillip Koeffler,et al. Myelodysplastic Bone Marrow Cells from Normal and + Characterization of Gene Expression of Cd34 , 2002 .
[85] M. Silva,et al. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. , 2002, Leukemia research.
[86] W. Hahn,et al. Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.
[87] J. Bennett,et al. The Myelodysplastic Syndromes: Morphology, risk assessment, and clinical management (2002) , 2002, International journal of hematology.
[88] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[89] M. Klintschar,et al. Two case studies of chronic idiopathic neutropenia preceding acute myeloid leukaemia , 1999, British journal of haematology.
[90] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[91] N. Heerema,et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. , 1997, American journal of clinical pathology.
[92] E. Kaiserling,et al. QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. , 1995, Journal of clinical pathology.
[93] J. Bennett,et al. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. , 1994, Leukemia research.
[94] J. Bennett,et al. Reference standards for bone marrow cellularity. , 1994, Leukemia research.
[95] H. Gralnick,et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.
[96] F. Cleton. Evolution of Cancer , 1991, British Journal of Cancer.
[97] J. Thiele,et al. Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens. , 1991, Journal of clinical pathology.
[98] M. Taniwaki,et al. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis , 1988, Cancer.
[99] G. Tricot,et al. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.
[100] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.